CompletedNot Applicable

A Non-interventional, Epidemiological, Registry-based Evaluation of Anaemia in Swedish Patients With Chronic Kidney Disease

Sweden14,415 participantsStarted 2018-09-24

Plain-language summary

The primary purpose of this study is to describe renal anemia treatment patterns in non-dialysis dependent (ND) and dialysis dependent (DD) populations, with a particular focus on iron use in erythropoiesis stimulating agent (ESA) treated patients. This study will also provide an epidemiological description of chronic kidney disease (CKD) associated anemia in relation to CKD stage, dialysis modality and underlying morbidity, as well as describe the relationship between inflammation and ESA treatment and describe the associated cardiovascular illness in ESA treated patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * For ND-CKD population: * all prevalent patients with a CKD with Estimated Glomerular filtration rate (eGFR) \< 45ml/min/1.73m2 with a recorded visit pre-dialysis in Swedish Renal Registry (SRR) in 2015 * Not on dialysis * For DD-CKD population * All prevalent patients taking part in the yearly cross-sectional dialysis investigation in SRR in 2015 * Dialysis dependent Exclusion Criteria: * not applicable

What they're measuring

Iron use in erythropoiesis stimulating agent (ESA) treated patients in the prevalent non-dialysis dependent (ND) population

Timeframe: 1 year (data from 2015)

Iron use in ESA treated patients in the prevalent dialysis dependent (DD) population

Timeframe: 1 year (data from 2015)

Trial details

NCT IDNCT03643601

SponsorAstellas Pharma a/s

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2018-12-04

View on ClinicalTrials.gov More Chronic Kidney Disease Associated Anemia trials